132 related articles for article (PubMed ID: 33550612)
1. Protein dynamics analysis identifies candidate cancer driver genes and mutations in TCGA data.
Sayılgan JF; Haliloğlu T; Gönen M
Proteins; 2021 Jun; 89(6):721-730. PubMed ID: 33550612
[TBL] [Abstract][Full Text] [Related]
2. Protein dynamics analysis reveals that missense mutations in cancer-related genes appear frequently on hinge-neighboring residues.
Sayılgan JF; Haliloğlu T; Gönen M
Proteins; 2019 Jun; 87(6):512-519. PubMed ID: 30785643
[TBL] [Abstract][Full Text] [Related]
3. Identifying Driver Interfaces Enriched for Somatic Missense Mutations in Tumors.
Ozturk K; Carter H
Methods Mol Biol; 2019; 1907():51-72. PubMed ID: 30542990
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive assessment of cancer missense mutation clustering in protein structures.
Kamburov A; Lawrence MS; Polak P; Leshchiner I; Lage K; Golub TR; Lander ES; Getz G
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):E5486-95. PubMed ID: 26392535
[TBL] [Abstract][Full Text] [Related]
5. Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.
Kumar S; Clarke D; Gerstein MB
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):18962-18970. PubMed ID: 31462496
[TBL] [Abstract][Full Text] [Related]
6. The mutational landscape of phosphorylation signaling in cancer.
Reimand J; Wagih O; Bader GD
Sci Rep; 2013 Oct; 3():2651. PubMed ID: 24089029
[TBL] [Abstract][Full Text] [Related]
7. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
[TBL] [Abstract][Full Text] [Related]
9. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
10. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
Narayan S; Bader GD; Reimand J
Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
[TBL] [Abstract][Full Text] [Related]
12. A pan-cancer atlas of somatic mutations in miRNA biogenesis genes.
Galka-Marciniak P; Urbanek-Trzeciak MO; Nawrocka PM; Kozlowski P
Nucleic Acids Res; 2021 Jan; 49(2):601-620. PubMed ID: 33406242
[TBL] [Abstract][Full Text] [Related]
13. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Analysis Reveals Cancer Missense Mutations Target Protein Interaction Interfaces.
Engin HB; Kreisberg JF; Carter H
PLoS One; 2016; 11(4):e0152929. PubMed ID: 27043210
[TBL] [Abstract][Full Text] [Related]
15. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers.
Tokheim C; Karchin R
Cell Syst; 2019 Jul; 9(1):9-23.e8. PubMed ID: 31202631
[TBL] [Abstract][Full Text] [Related]
16. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
17. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues.
Molina-Vila MA; Nabau-Moretó N; Tornador C; Sabnis AJ; Rosell R; Estivill X; Bivona TG; Marino-Buslje C
Hum Mutat; 2014 Mar; 35(3):318-28. PubMed ID: 24323975
[TBL] [Abstract][Full Text] [Related]
18. Computational Approaches to Prioritize Cancer Driver Missense Mutations.
Zhao F; Zheng L; Goncearenco A; Panchenko AR; Li M
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30037003
[TBL] [Abstract][Full Text] [Related]
19. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
